PT115056A - Formas amorfas de agentes quelantes e seus métodos de preparação - Google Patents
Formas amorfas de agentes quelantes e seus métodos de preparaçãoInfo
- Publication number
- PT115056A PT115056A PT115056A PT11505618A PT115056A PT 115056 A PT115056 A PT 115056A PT 115056 A PT115056 A PT 115056A PT 11505618 A PT11505618 A PT 11505618A PT 115056 A PT115056 A PT 115056A
- Authority
- PT
- Portugal
- Prior art keywords
- agents
- cheling
- amorphic
- preparation methods
- production
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/76—Metal complexes of amino carboxylic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- General Preparation And Processing Of Foods (AREA)
- Non-Alcoholic Beverages (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A PRESENTE INVENÇÃO REFERE-SE A UMA NOVA FORMA AMORFA E ESTÁVEL DE AGENTES QUELANTES, PARA COMPOSIÇÕES E OUTROS USOS, BEM COMO AO PROCESSO DE PRODUÇÃO DA MESMA ESPECIALMENTE NA FORMA DE PARTÍCULAS. MAIS ESPECIFICAMENTE, ESTA INVENÇÃO REFERE-SE A UM PROCESSO DE PRODUÇÃO DE AGENTES QUELANTES ESSENCIALMENTE AMORFOS ATRAVÉS DA DISSOLUÇÃO DOS MESMOS NUM SOLVENTE ADEQUADO OU NUMA MISTURA DE SOLVENTES, OPCIONALMENTE PURIFICANDO A SOLUÇÃO E ISOLANDO AS PARTÍCULAS DE AGENTE QUELANTE AMORFO ATRAVÉS DA REMOÇÃO DE SOLVENTE, PREFERIVELMENTE POR SECAGEM POR ATOMIZAÇÃO. ALÉM DISSO, AS PARTÍCULAS AMORFAS PRODUZIDAS DE ACORDO COM O PROCESSO DA PRESENTE INVENÇÃO APRESENTAM CARACTERÍSTICAS VANTAJOSAS NO QUE REFERE À CONSISTÊNCIA ENTRE LOTES E SOLUBILIDADE. ESTES AGENTES PODEM SER UTILIZADOS NA ÁREA FARMACÊUTICA PARTICULARMENTE EM NOVAS FORMULAÇÕES TENDO ESTES EXCIPIENTES NA COMPOSIÇÃO.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT115056A PT115056B (pt) | 2018-10-04 | 2018-10-04 | Formas amorfas de agentes quelantes e seus métodos de preparação |
KR1020217013330A KR20210078503A (ko) | 2018-10-04 | 2019-10-03 | 킬레이트화제의 무정형 형태 및 이들의 제조방법 |
AU2019354251A AU2019354251A1 (en) | 2018-10-04 | 2019-10-03 | Amorphous form of chelating agents and process for preparing them |
PCT/GB2019/052799 WO2020070508A1 (en) | 2018-10-04 | 2019-10-03 | Amorphous form of chelating agents and process for preparing them |
EP19790705.8A EP3860973A1 (en) | 2018-10-04 | 2019-10-03 | Amorphous form of chelating agents and process for preparing them |
US17/281,732 US20220002226A1 (en) | 2018-10-04 | 2019-10-03 | Amorphous Form of Chelating Agents and Process for Preparing them |
CA3114278A CA3114278A1 (en) | 2018-10-04 | 2019-10-03 | Amorphous form of chelating agents and process for preparing them |
JP2021516727A JP2022503804A (ja) | 2018-10-04 | 2019-10-03 | キレート化剤の非晶質形態及びそれを調製する方法 |
CN201980065426.6A CN113015718A (zh) | 2018-10-04 | 2019-10-03 | 螯合剂的无定形形式及其制备方法 |
IL281892A IL281892A (en) | 2018-10-04 | 2021-03-29 | Amorphous form of chelating agents and process for preparing them |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT115056A PT115056B (pt) | 2018-10-04 | 2018-10-04 | Formas amorfas de agentes quelantes e seus métodos de preparação |
Publications (2)
Publication Number | Publication Date |
---|---|
PT115056A true PT115056A (pt) | 2020-07-24 |
PT115056B PT115056B (pt) | 2021-12-10 |
Family
ID=68296519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT115056A PT115056B (pt) | 2018-10-04 | 2018-10-04 | Formas amorfas de agentes quelantes e seus métodos de preparação |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220002226A1 (pt) |
EP (1) | EP3860973A1 (pt) |
JP (1) | JP2022503804A (pt) |
KR (1) | KR20210078503A (pt) |
CN (1) | CN113015718A (pt) |
AU (1) | AU2019354251A1 (pt) |
CA (1) | CA3114278A1 (pt) |
IL (1) | IL281892A (pt) |
PT (1) | PT115056B (pt) |
WO (1) | WO2020070508A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114053859B (zh) * | 2021-11-17 | 2023-08-18 | 重庆科技学院 | 一种硫化氢脱除剂及其制备方法 |
WO2023245463A1 (en) * | 2022-06-21 | 2023-12-28 | L'oreal | A stabilized composition comprising a thiopyridinone compound and chelating agent |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU797224A1 (ru) * | 1979-04-12 | 1998-02-20 | Институт химической кинетики и горения Сибирского отделения АН СССР | Способ получения винилидендифосфоновой кислоты или ее натриевых солей |
US4636336A (en) * | 1984-11-02 | 1987-01-13 | Rockwell International Corporation | Process for drying a chelating agent |
US4978763A (en) * | 1988-09-27 | 1990-12-18 | Salutar, Inc. | Novel manganese(II) DTPA chelate |
KR100249323B1 (ko) | 1997-12-09 | 2000-03-15 | 이상현 | 고순도 에틸렌디아민4아세트산4나트륨염의 제조방법 |
CN1190413C (zh) * | 2001-12-19 | 2005-02-23 | 钟林 | 乙二胺四乙酸络合金属盐的生产方法 |
US7872144B2 (en) * | 2005-06-13 | 2011-01-18 | Jubilant Organosys Limited | Process for producing biphosphonic acids and forms thereof |
WO2010092446A1 (en) * | 2009-01-19 | 2010-08-19 | Orchid Chemicals & Pharmaceuticals Ltd | Pharmaceutical composition comprising cilastatin, a chelating agent and opt. a penem antibiotic |
MX2012008482A (es) * | 2010-01-22 | 2012-11-29 | Hyprotek Inc | Agentes antimicrobianos que comprenden peroxido, alcohol y agente quelatador. |
CN102229620B (zh) * | 2011-04-27 | 2014-05-28 | 河南清水源科技股份有限公司 | 一种高纯度固体羟基亚乙基二膦酸四钠盐及其生产工艺 |
CN102875400B (zh) * | 2012-09-21 | 2014-08-06 | 万华化学集团股份有限公司 | 一种制备二乙烯三胺五乙酸的方法 |
-
2018
- 2018-10-04 PT PT115056A patent/PT115056B/pt active IP Right Grant
-
2019
- 2019-10-03 CN CN201980065426.6A patent/CN113015718A/zh active Pending
- 2019-10-03 CA CA3114278A patent/CA3114278A1/en active Pending
- 2019-10-03 KR KR1020217013330A patent/KR20210078503A/ko not_active Application Discontinuation
- 2019-10-03 US US17/281,732 patent/US20220002226A1/en active Pending
- 2019-10-03 EP EP19790705.8A patent/EP3860973A1/en active Pending
- 2019-10-03 JP JP2021516727A patent/JP2022503804A/ja active Pending
- 2019-10-03 WO PCT/GB2019/052799 patent/WO2020070508A1/en active Search and Examination
- 2019-10-03 AU AU2019354251A patent/AU2019354251A1/en active Pending
-
2021
- 2021-03-29 IL IL281892A patent/IL281892A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL281892A (en) | 2021-05-31 |
KR20210078503A (ko) | 2021-06-28 |
AU2019354251A1 (en) | 2021-04-15 |
CA3114278A1 (en) | 2020-04-09 |
EP3860973A1 (en) | 2021-08-11 |
PT115056B (pt) | 2021-12-10 |
JP2022503804A (ja) | 2022-01-12 |
WO2020070508A1 (en) | 2020-04-09 |
US20220002226A1 (en) | 2022-01-06 |
CN113015718A (zh) | 2021-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020003296A1 (es) | Formulación farmacéutica de odevixibat | |
BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
BR112014028643A8 (pt) | Profármaco de alta penetração, seus usos, e composição farmacêutica | |
BR112014016648A2 (pt) | derivados policíclicos, processo de preparação e uso farmacêutico dos mesmos | |
PT115056A (pt) | Formas amorfas de agentes quelantes e seus métodos de preparação | |
BR112016025126A2 (pt) | formulação líquida compreendendo composto neutralizante de gm-csf | |
BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0519280A2 (pt) | composto, composiÇço farmacÊutica e uso de um composto | |
BR112017026287A2 (pt) | composições de hidroxipropil beta-ciclodextrina e métodos | |
BR112019006463A2 (pt) | composição oral de canabinoides extraídos e métodos de uso da mesma | |
BR112015009259B8 (pt) | Composição aquosa compreendendo o composto de neutralização do gm-csf | |
PE20171246A1 (es) | Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para la preparacion y uso de los mismos | |
JP2017514924A5 (pt) | ||
BR112013026153A2 (pt) | Composição farmacêutica; uso de pelo menos um éter de celulose não iônico; método parapreparar uma composição farmacêutica; método para tratar e/ou prevenir um distúrbioclimatérico; uso de uma composição farmacêutica; e kit | |
BR112014016472A8 (pt) | formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo | |
BR112014027047A2 (pt) | nova formulação | |
AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
BR112013019876A2 (pt) | formulação farmacêutica, uso da formulação farmacêutica, frasco e kit | |
AR098333A1 (es) | Una composición en forma de polvo | |
PT110209A (pt) | Formas polimórficas de trifenatato de vilanterol e processos para a preparação das mesmas. | |
BR112012010400A2 (pt) | composição co-processada, processo para preparar uma composição útil como um excipiente farmacêutico, formulação de granulado ou comprimido, método, e, forma de dosagem sólida | |
BR112022017509A2 (pt) | Composições terapêuticas de liberação prolongada estáveis em solventes polares apróticos e métodos de fabricação das mesmas | |
BR112021023549A2 (pt) | Composições terapêuticas estáveis em solventes polares apróticos e seus métodos de fabricação | |
BR112015018200A2 (pt) | composição mastigável para administração oral e processo para preparar a mesma | |
AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BB1A | Laying open of patent application |
Effective date: 20200721 |
|
FG3A | Patent granted, date of granting |
Effective date: 20211206 |